Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548. https://doi.org/10.1016/S1470-2045(14)70442-5

Article  PubMed  Google Scholar 

Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DL, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9:e670–e677. https://doi.org/10.1016/S2352-3026(22)00165-X

Article  CAS  PubMed  Google Scholar 

Cancer Research UK. Myeloma statistics | Cancer Research UK. Myeloma Statistics. 2017. Accessed March 31, 2021. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/survival2018

Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood. 2015;125:410–2. https://doi.org/10.1182/blood-2014-10-609461

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russell SJ, Peng K-W. Oncolytic virotherapy: a contest between apples and oranges. Mol Ther. 2017;25:1107–16. https://doi.org/10.1016/j.ymthe.2017.03.026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakhawat A, Ma L, Muhammad T, Khan AA, Chen X, Huang Y. A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma. Sci Rep. 2019;9:1–11. https://doi.org/10.1038/s41598-019-43668-8.

Article  CAS  Google Scholar 

Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp). 2014;4:26–33. https://doi.org/10.1556/EuJMI.4.2014.1.2

Article  CAS  PubMed  Google Scholar 

Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–3. https://doi.org/10.1126/science.275.5304.1320

Article  CAS  PubMed  Google Scholar 

Nemerow GR, Pache L, Reddy V, Stewart PL. Insights into adenovirus host cell interactions from structural studies. Virology. 2009;384:380–8. https://doi.org/10.1016/j.virol.2008.10.016

Article  CAS  PubMed  Google Scholar 

Cervera-Carrascon V, Havunen R, Hemminki A. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. Expert Opin Biol Therapy. 2019;19:443–55. https://doi.org/10.1080/14712598.2019.1595582

Article  CAS  Google Scholar 

Mantwill K, Klein FG, Wang D, Hindupur SV, Ehrenfeld M, Holm PS, et al. Concepts in oncolytic adenovirus therapy. Int J Mol Sci. 2021;22:10522 https://doi.org/10.3390/IJMS221910522

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muthana M, Rodrigues S, Chen Y-Y, Welford A, Hughes R, Tazzyman S, et al. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Res. 2013;73:490–5. https://doi.org/10.1158/0008-5472.CAN-12-3056

Article  CAS  PubMed  Google Scholar 

Qi Y, Guo H, Hu N, Dongyun H, Zhang S, Chu Y, et al. Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus. Toxicol Appl Pharmacol. 2014;280:362–9. https://doi.org/10.1016/J.TAAP.2014.08.008

Article  CAS  PubMed  Google Scholar 

Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A Phase I study of telomerase-specific replication competent oncolytic adenovirus (Telomelysin) for various solid tumors. Mol Ther. 2010;18:429–34. https://doi.org/10.1038/mt.2009.262

Article  CAS  PubMed  Google Scholar 

Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, et al. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 2009;16:1441–51. https://doi.org/10.1038/GT.2009.103

Article  CAS  PubMed  Google Scholar 

Ashour R, Ri M, Aly SS, Yoshida T, Tachita T, Kanamor T, et al. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma. Int J Hematol. 2019;110:69–76. https://doi.org/10.1007/s12185-019-02649-3

Article  PubMed  Google Scholar 

Fancher M, Bunk E. Elotuzumab: the first monoclonal antibody for the treatment of multiple myeloma. J Adv Pract Oncol. 2016;7:542 https://doi.org/10.6004/jadpro.2016.7.5.6

Article  PubMed  Google Scholar 

Zhou X, Rasche L, Kortüm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2022;108:958 https://doi.org/10.3324/HAEMATOL.2020.266841

Article  PubMed Central  Google Scholar 

Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, et al. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 2023;6:169 https://doi.org/10.20517/CDR.2022.138

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paton-Hough J, Chantry AD, Lawson MA. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease. Bone. 2015;77:57–68. https://doi.org/10.1016/j.bone.2015.04.004

Article  CAS  PubMed  Google Scholar 

Chen CY, Senac JS, Weaver EA, May SM, Jelinek DF, Greipp P, et al. Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res. 2011;17:6712–22. https://doi.org/10.1158/1078-0432.CCR-11-0968

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001;8:930–7. https://doi.org/10.1038/sj.gt.3301488

Article  CAS  PubMed  Google Scholar 

Shlomovitz I, Speir M, Gerlic M. Flipping the dogma - phosphatidylserine in non-apoptotic cell death. Cell Commun Signal. 2019;17:1–12. https://doi.org/10.1186/s12964-019-0437-0

Article  Google Scholar 

Laevskaya A, Borovjagin A, Timashev PS, Lesniak MS, Ulasov I. Metabolome-driven regulation of adenovirus-induced cell death. Int J Mol Sci. 2021;22:464 https://doi.org/10.3390/IJMS22010464.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feola S, Russo S, Ylösmäki E, Cerullo V. Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol Ther. 2022;236:108103 https://doi.org/10.1016/J.PHARMTHERA.2021.108103

Article  CAS  PubMed  Google Scholar 

Serrano-del Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol. 2019;7. https://doi.org/10.3389/fcell.2019.00050

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM, et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res. 2014;20:5946–55. https://doi.org/10.1158/1078-0432.CCR-14-1404

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021;93:4668–92. https://doi.org/10.1002/JMV.26947

Article  CAS  PubMed  Google Scholar 

Skorda A, Sklirou AD, Sakellaropoulos T, Gianniou DD, Kastritis E, Terpos E, et al. Non‐lethal proteasome inhibition activates pro‐tumorigenic pathways in multiple myeloma cells. J Cell Mol Med. 2019;23:8010 https://doi.org/10.1111/JCMM.14653

Article  CAS  PubMed  PubMed Central